BBC News and Press, Virtus LifeSci Biotech Clinical Trials From 04/16/24

2024-04-16 10:30:00 ET Summary The rise in rates last week pushed the 10-year to its highest level since the peak at 5% in October of last year. Gold has been setting new highs, trading above $2400 at one point on Friday before succumbing to some profit taking. Year-to-date, t...

2024-04-15 09:50:00 ET Summary Powerful investment themes, such as AI, can capture the market’s collective imagination. Taken to an extreme, however, they can also trigger distortions across and within the markets. In our 2Q 2024 Equity Outlook, we examine key historic dist...

2024-04-09 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-22 11:15:00 ET Summary A positive January for U.S. stocks is typically a prelude to a positive year, with our analysis finding the correlation to hold 80% of the time since 1928. Stocks look well-positioned to outperform bonds and cash again this year, but high valuations ...

2024-03-19 02:50:00 ET Summary Typically, a back-up in rates has led to a sell-off in stocks. We believe the current environment is different for three reasons: the degree of the move in rates, current economic cycle, and strength of mega-cap technology. In this environment, we wo...

2024-03-13 10:10:00 ET Summary Jeff Hirsch, editor-in-chief of The Stock Trader’s Almanac, and Carter Worth, CEO and founder of Worth Charting, discuss their outlook for 2024 with MoneyShow's Mike Larson. Jeff expects a strong year for stocks, with gains of 8-15% broadly sp...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-02-23 04:05:00 ET Summary Within healthcare, an area that has been negatively impacted the last couple of years is the pharmaceutical manufacturing value chain. Several capital goods and materials sectors experienced recessionary conditions last year, which caused weak fundam...

2024-02-07 01:53:00 ET Summary A sub-$3trn 2023 for M&A, but new year pipeline gives hope. Rising follow-on equity in 2023 signals latent appetite. Unstoppable debt capital markets hit $8.9trn for FY2023. By Lucille Jones, Senior Manager, Deals Intelligence and...

2024-01-31 04:36:00 ET Summary 2023 was characterized by narrow leadership and multiple expansions. While last year’s gains have led to headline valuations appearing stretched, there are many segments of the market that are not as aggressively priced. With the expectati...